<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04052425</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 18424-306</org_study_id>
    <nct_id>NCT04052425</nct_id>
  </id_info>
  <brief_title>Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)</brief_title>
  <official_title>Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1): A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in&#xD;
      adolescent and adult participants with non-segmental vitiligo for whom total body involved&#xD;
      vitiligo area (facial and nonfacial) does not exceed 10% body surface area (BSA).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 20, 2019</start_date>
  <completion_date type="Anticipated">October 30, 2021</completion_date>
  <primary_completion_date type="Actual">April 18, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Participants will receive ruxolitinib cream or vehicle for 24 weeks, after which they will be offered the opportunity to continue in the treatment extension period. Participants initially randomized to vehicle will be crossed over to active drug, and participants treated with ruxolitinib cream will receive an additional 28 weeks of treatment with ruxolitinib cream.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants achieving F-VASI75</measure>
    <time_frame>Week 24</time_frame>
    <description>≥ 75% improvement from baseline in Face Vitiligo Area Scoring Index (F-VASI) score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage change from baseline in facial body surface area (F-BSA)</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving F-VASI50</measure>
    <time_frame>Week 24</time_frame>
    <description>≥ 50% improvement from baseline in F-VASI score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving F-VASI75</measure>
    <time_frame>Week 52</time_frame>
    <description>≥ 75% improvement from baseline in F-VASI score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving F-VASI90</measure>
    <time_frame>Week 24</time_frame>
    <description>≥ 90% improvement from baseline in F-VASI score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving F-VASI90</measure>
    <time_frame>Week 52</time_frame>
    <description>≥ 90% improvement from baseline in F-VASI score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving T-VASI50</measure>
    <time_frame>Week 24</time_frame>
    <description>≥ 50% improvement in total body Vitiligo Area Scoring Index (T-VASI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving T-VASI50</measure>
    <time_frame>Week 52</time_frame>
    <description>≥ 50% improvement in T-VASI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving T-VASI75</measure>
    <time_frame>Week 52</time_frame>
    <description>≥ 75% improvement in T-VASI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving a Vitiligo Noticeability Scale (VNS) of &quot;4 - A lot less noticeable&quot; or &quot;5 - No longer noticeable&quot;</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment-emergent adverse events</measure>
    <time_frame>Up to 56 weeks</time_frame>
    <description>Any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving F-VASI25/50/75/90</measure>
    <time_frame>During the treatment period (double-blind and treatment extension periods), up to 52 weeks.</time_frame>
    <description>≥ 25%/ 50%/ 75%/90% improvement from baseline in F-VASI score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change from baseline in F-VASI</measure>
    <time_frame>From baseline to during the treatment period (double-blind and treatment extension periods), up to 52 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change from baseline in F-BSA</measure>
    <time_frame>From baseline to during the treatment period (double-blind and treatment extension periods), up to 52 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change from baseline in T-VASI</measure>
    <time_frame>From baseline to during the treatment period (double-blind and treatment extension periods), up to 52 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change from baseline in total body surface area (T-BSA)</measure>
    <time_frame>From baseline to during the treatment period (double-blind and treatment extension periods), up to 52 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving T-VASI25/50/75/90</measure>
    <time_frame>During the treatment period (double-blind and treatment extension periods), up to 52 weeks.</time_frame>
    <description>≥ 25%/ 50%/ 75%/90% improvement in T-VASI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants in each category of VNS</measure>
    <time_frame>During the treatment period (double-blind and treatment extension periods), up to 52 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population-based (trough) plasma concentrations of ruxolitinib</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population-based (trough) plasma concentrations of ruxolitinib</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population-based (trough) plasma concentrations of ruxolitinib</measure>
    <time_frame>Week 40</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">330</enrollment>
  <condition>Non-segmental Vitiligo</condition>
  <arm_group>
    <arm_group_label>Ruxolitinib cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ruxolitinib cream 1.5% twice daily (BID) for 24 weeks followed by ruxolitinib cream 1.5% BID for an additional 28-week treatment extension period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle cream for 24 weeks followed by crossover to ruxolitinib cream 1.5% BID in a 28-week treatment extension period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib cream</intervention_name>
    <description>Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.</description>
    <arm_group_label>Ruxolitinib cream</arm_group_label>
    <other_name>INCB018424 cream</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Vehicle cream is a topical formulation applied as a thin film to affected areas.</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of non-segmental vitiligo with depigmented area including ≥ 0.5%&#xD;
             BSA on the face, ≥ 0.5 F-VASI, ≥ 3% BSA on nonfacial areas, ≥ 3 T-VASI, and total body&#xD;
             vitiligo area (facial and nonfacial) not exceeding 10% BSA.&#xD;
&#xD;
          -  Agree to discontinue all agents used to treat vitiligo from screening through the&#xD;
             final safety follow-up visit. Over-the-counter preparations deemed acceptable by the&#xD;
             investigator and camouflage makeups are permitted.&#xD;
&#xD;
          -  Must be willing to take appropriate contraceptive measures to avoid pregnancy or&#xD;
             fathering a child for the duration of study participation.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  No pigmented hair within any of the vitiligo areas on the face.&#xD;
&#xD;
          -  Other forms of vitiligo (eg, segmental) or other differential diagnosis of vitiligo or&#xD;
             other skin depigmentation disorders (eg, piebaldism, pityriasis alba, leprosy,&#xD;
             postinflammatory hypopigmentation, progressive macule hypomelanosis, nevus anemicus,&#xD;
             chemical leukoderma, and tinea versicolor).&#xD;
&#xD;
          -  Have used depigmentation treatments (eg, monobenzone) for past treatment of vitiligo&#xD;
             or other pigmented areas.&#xD;
&#xD;
          -  Use of protocol-defined treatments within the indicated washout period before&#xD;
             baseline.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen Butler, MD</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cahaba Dermatology</name>
      <address>
        <city>Hoover</city>
        <state>Alabama</state>
        <zip>35244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cognitive Clinical Trials Scottsdale Btc Ppds</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Burke Pharmaceutical Research</name>
      <address>
        <city>Hot Springs National Park</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Oc Dermatology</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marvel Clinical Research Llc</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rady Children'S Hospital - San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco Sub Location</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Ct</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <zip>06810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harmony Medical Research Institute</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Marcus Research Clinic Inc.</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ForCare Medical Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forcare Clinical Research Fcr Forward Clinical Trials, Inc</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33624</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metabolic Research Institute Inc</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Management Llc</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Lakes Research Group Inc</name>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <zip>48706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Specialists of Brighton</name>
      <address>
        <city>Brighton</city>
        <state>Michigan</state>
        <zip>48114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suny Downstate Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Hills Dermatology Group</name>
      <address>
        <city>Forest Hills</city>
        <state>New York</state>
        <zip>11375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Dermatology Specialists Greenwich</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates Llc</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kgl Skin Study Center</name>
      <address>
        <city>Broomall</city>
        <state>Pennsylvania</state>
        <zip>19008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Associates of Plymouth Meeting</name>
      <address>
        <city>Plymouth Meeting</city>
        <state>Pennsylvania</state>
        <zip>19462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Clinical Trial Services</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Clinical Research Tennessee Llc</name>
      <address>
        <city>Murfreesboro</city>
        <state>Tennessee</state>
        <zip>37130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Progressive Clinical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Clinical Research Center of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Specialists of Spokane</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital For Active Treatement - Clinic of Dermatology and Venerology</name>
      <address>
        <city>Pleven</city>
        <zip>05800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DCC 28</name>
      <address>
        <city>Sofia</city>
        <zip>01592</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Eurohealth</name>
      <address>
        <city>Sofia</city>
        <zip>01606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Institute</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T1Y 0B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute For Skin Advancement</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3A 2N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Centre For Dermatology</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J 5K2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Windsor Clinical Research Inc</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 5L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre / Carey/Wang Clinic</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3Z2S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siena Medical Reserch Corporation</name>
      <address>
        <city>Westmount</city>
        <state>Quebec</state>
        <zip>H3Z 2S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Nice - Hopital L'Archet 1</name>
      <address>
        <city>Nice Cedex 3</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Charles Nicolle Chu Rouen - Hopital de Bois-Guillaume</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Toulouse Hopital Larrey Centre de Reference Des Maladies Rares de La Peau Service de Dermatol</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinic Carl Gustav Carus, Technical University Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinik Munster Dermatologie</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero Piero Palagi</name>
      <address>
        <city>Firenze</city>
        <zip>50125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Dermatologico San Gallicano</name>
      <address>
        <city>Rome</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus - Polska Sp Z Oo Oddzial W Gdansk</name>
      <address>
        <city>Gdansk</city>
        <zip>80-382</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Sp. Z O.O. Oddzial W Gdyni</name>
      <address>
        <city>Gdynia</city>
        <zip>81-537</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus - Sp Z Oo Oddzial W Katowice</name>
      <address>
        <city>Katowice</city>
        <zip>40-040</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermedic Dr. Zdybski</name>
      <address>
        <city>Ostrowiec</city>
        <zip>27-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Sp. Z O.O. Oddzial W Poznaniu</name>
      <address>
        <city>Poznan</city>
        <zip>60-702</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poradnia Dermatologiczno-Wenerologiczna Mediderm S.C. Nzoz</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Sp. Z O.O. Oddzial We Wroclawiu</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-381</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Cima Sanitas</name>
      <address>
        <city>Barcelona</city>
        <zip>08034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Cecilio</name>
      <address>
        <city>Granada</city>
        <zip>18016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra (Cun)</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 8, 2019</study_first_submitted>
  <study_first_submitted_qc>August 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2019</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitiligo</keyword>
  <keyword>non-segmental</keyword>
  <keyword>JAK inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitiligo</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

